Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis

Trial Profile

An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Azathioprine
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Focus Registrational; Therapeutic Use
  • Acronyms RITAZAREM
  • Most Recent Events

    • 20 Jul 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
    • 07 Mar 2017 According to study protocol and trial design data published in Trials Journal, the enrollment for this study was completed on 21 Nov 2016 and thus randomization will be completed by the end of Mar 2017.The primary endpoint will be reported in 2019, and the final trial report in 2020.
    • 21 Feb 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top